Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response.

MLA

Vija Racaru, Lavinia, et al. “Clinical Outcomes 1 Year after Empiric 131I Therapy for Hyperthyroid Disorders: Real Life Experience and Predictive Factors of Functional Response.” Nuclear Medicine Communications, vol. 38, no. 9, Sept. 2017, pp. 756–63. EBSCOhost, https://doi.org/10.1097/MNM.0000000000000705.

APA

Vija Racaru, L., Fontan, C., Bauriaud-Mallet, M., Brillouet, S., Caselles, O., Zerdoud, S., Bastié, D., Vallot, D., Caron, P., Bardiès, M., & Courbon, F. (2017). Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nuclear Medicine Communications, 38(9), 756–763. https://doi.org/10.1097/MNM.0000000000000705

Chicago

Vija Racaru, Lavinia, Charlotte Fontan, Mathilde Bauriaud-Mallet, Séverine Brillouet, Olivier Caselles, Slimane Zerdoud, Delphine Bastié, et al. 2017. “Clinical Outcomes 1 Year after Empiric 131I Therapy for Hyperthyroid Disorders: Real Life Experience and Predictive Factors of Functional Response.” Nuclear Medicine Communications 38 (9): 756–63. doi:10.1097/MNM.0000000000000705.